参考文献/References:
[1] Herbst RS,Heymach JV,Lippman SM.Lung cancer.N Engl J Med,2008,359(13):1367-1380.
[2] Herbst RS,Fukuoka M,Baselga J.Gefitinib-a novel targeted approach to treating cancer.Nat Rev Cancer,2004,4(12):956-965.
[3] Shepherd FA,Rodrigues PJ,Ciuleanu T,et al,Erlotinib in previ-ously treated non-small-cell lung cancer.N Engl J Med,2005,353(2):123-132.
[4] Rizvi NA,Rusch V,Pao W,et al.Molecular characteristics predict clinical outcomes:prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sen-sitizing mutations in the tyrosine binding domain of the EGFR gene.Clin Cancer Res,2011,17(10):3500-3506.
[5] Sawyers CL.The cancer biomarker problem.Nature,2008,452(7187):548-552.
[6] Zhou Q,Zhang XC,Chen ZH,et al.Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.J Clin Oncol,2011,29(24):3316-3321.
[7] Sharma SV, Bell DW, Settleman J,et al.Epidermal growth factor receptor mutations in lung cancer.Nat Rev Cancer,2007,7(3):169-181.
[8] Memon AA,Jakobsen S,Dagnaes-Hansen F,et al.Positron emis-sion tomography (PET) imaging with [11C]-labeled erlotinib:a micro-PET study on mice with lung tumor xenografts.Cancer Res,2009,69(3):873-878.
[9] Meng X,Loo BW Jr,Ma L,et al.Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI:a pilot study.J Nucl Med,2011,52(10):1573-1579.
[10] Theeraladanon C,Takahashi N,Shiina M,et al.Rational approachto the synthesis,evaluation,and 68ga labeling of a novel 4-anilino-quinoline epidermal growth factor receptor inhibitor as a new imag-ing agent that selectively targets the epidermal growth factor recep-tor tyrosine kinase.Cancer Biother Radiopharm,2010,25(4):479-485.
[11] Bourkoula A,Paravatou-Petsotas M,Papadopoulos A,et al.Synthe-sis and characterization of rhenium and technetium-99m tricarbonyl complexes bearing the 4-[3-bromophenyl] quinazoline moiety as abiomarker for EGFR-TK imaging.Eur J Med Chem,2009,44(10):4021-4027.
[12] Hirata M,Kanai Y,Naka S,et al.Evaluation of radioiodinated quinazoline derivative as a new ligand for EGF receptor tyrosine kinase activity using SPECT.Ann Nucl Med,2011,25(2):117-124.
[13] Fozing T,Scheuer C,Samnick S.Synthesis and initial tumor affinity testing of iodine-123 labelled EGFR-affine agents as potential imaging probes for hormone-refractory prostate cancer.Eur J Med Chem,2010,45(9):3780-3786.
[14] Mishani E,Hagooly A.Strategies for molecular imaging of epider-mal growth factor receptor tyrosine kinase in cancer.J Nucl Med,2009,50(8):1199-1202.
[15] Pantaleo MA,Mishani E,Nanni C,et al.Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.Mol Imaging Biol,2010,12(6):616-625.
[16] Mishani E,Abourbeh G,Eiblmaier M,et al.Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.Curr Pharm Des,2008,14(28):2983-2998.
[17] Gelovani JG.Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emis-sion tomography.Cancer Metastasis Rev,2008,27(4):645-653.
[18] Pal A,Balatoni JA,Mukhopadhyay U,et al.Radiosynthesis and ini-tial in vitro evaluation of [18F] F-PEG6-IPQA-a novel PET radiotrac-er for imaging EGFR expression-activity in lung carcinomas.Mol Imaging Biol,2011,13(5):853-861.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]杨洋,樊赛军.LXXLL模体在雌激素受体信号通路中的作用及应用价值[J].国际放射医学核医学杂志,2014,38(1):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
Yang Yang,Fan Saijun.Role of LXXLL motif in modulation of estrogen receptor signaling and its potential application[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):22.[doi:10.3760/cma.j.issn 1673-4114.2014.01.006]
[3]白庆双,李宁,方佩华,等.人血清TRAb酶联免疫吸附试验检测在甲状腺疾病患者中的临床应用[J].国际放射医学核医学杂志,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
Bai Qingshuang,Li Ning,Fang Peihua,et al.The clinical application of human serum level of the TRAb measured by enzyme-linked immunosorbent assay in patients with thyroid diseases[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):80.[doi:10.3760/cma.j.issn.1673-4114.2014.02.003]
[4]李丽,赵长久,田国梅.CXC型趋化因子受体4及其分子显像剂在肿瘤方面的研究进展[J].国际放射医学核医学杂志,2014,38(3):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
Li Li,Zhao Changjiu,Tian Guomei.Research progress of CXC chemokine receptor type 4 and molecular imaging in tumors[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):190.[doi:10.3760/cma.j.issn.1673-4114.2014.03.012]
[5]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[6]袁杰,刘兴党,韩梅.SPECT、PET神经受体和转运体显像技术在海洛因成瘾研究中的应用[J].国际放射医学核医学杂志,2013,37(1):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
YUAN Jie,LIU Xing-dang,HAN Mei.Neuroreceptor and its transporters imaging by PET and SPECT in heroin addiction[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(2):30.[doi:10.3760/cma.j.issn.1673-4114.2013.01.009]
[7]鲍伟奇,邱春,管一晖.γ-氨基丁酸A型-苯二氮革受体显像剂在神经系统疾病中的应用[J].国际放射医学核医学杂志,2012,36(1):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
BAO Wei-qi,QIU Chun,GUAN Yi-hui.Application of gamma-aminobutyric acid type A-benzodiazepine receptor imaging for study of neuropsychiatric disorders[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):1.[doi:10.3760/cma.j.issn.1673-4114.2012.01.001]
[8]程维维,王辉.促甲状腺激素受体与甲状腺癌关系的研究进展[J].国际放射医学核医学杂志,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
CHENG Wei-wei,WANG Hui.Progress in the relationship of thyroid-stimulating hormone receptor and thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
[9]黄丽娟,陈宁,叶静,等.反义肽核酸对促甲状腺激素受体mRNA表达的影响[J].国际放射医学核医学杂志,2012,36(5):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
HUANG Li-juan,CHEN Ning,YE Jing,et al.The effects of antisense peptide nucleic acid on the expression of thyroid stimulating hormone receptor mRNA[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):310.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.011]
[10]刘淼,刘兴党.生长抑素受体显像剂99Tcm-奥曲肽的SPECT研究[J].国际放射医学核医学杂志,2012,36(3):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
LIU Miao,LIU Xing-dang.Development of study on SPECT imaging with radioisotope 99Tcm-octreotide[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):138.[doi:10.3760/cma.j.issn.1673-4114.2012.03.003]
[11]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[12]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[13]柳杰,刘佩芳.乳腺癌X射线征象与雌激素受体、孕激素受体和C-erbB-2表达相关性的研究进展[J].国际放射医学核医学杂志,2012,36(5):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
LIU Jie LIU,Pei-fang.Development of the correlation study between mammographic appearances and expression of estrogen receptor, progesterone receptor and C-erbB-2 in patients with breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(2):301.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.009]
[14]王相成,王雪梅,何玉林,等.PET-CT表皮生长因子受体显像的研究进展[J].国际放射医学核医学杂志,2010,34(5):266.[doi:10.3760/cma.j.issn.1673-4114.2010.05.003]
WANG Xiang-cheng,WANG Xue-mei,HE Yu-lin,et al.Study progress of PET-CT epidermal growth factor receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):266.[doi:10.3760/cma.j.issn.1673-4114.2010.05.003]
[15]汪永红,陈文新,何品玉.肿瘤表皮生长因子受体的分子显像研究[J].国际放射医学核医学杂志,2009,33(4):204.[doi:10.3760/cma.j.issn.1673-4114.2009.04.004]
WANG Yong-hong,CHEN Wen-xin,HE Pin-yu.Tumor epidermal growth factor receptor molecular imaging research[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(2):204.[doi:10.3760/cma.j.issn.1673-4114.2009.04.004]
[16]黄顺,韩彦江,郑希,等.靶向表皮生长因子受体小分子类PET显像剂研究进展[J].国际放射医学核医学杂志,2017,41(1):50.[doi:10.3760/cma.j.issn.1673-4114.2017.01.010]
Huang Shun,Han Yanjiang,Zheng Xi,et al.PET imaging agents of small molecules inhibitors targeting EGFR[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(2):50.[doi:10.3760/cma.j.issn.1673-4114.2017.01.010]
[17]郑玉民,王自正,王峰,等.以表皮生长因子受体为靶点的肿瘤分子靶向治疗[J].国际放射医学核医学杂志,2007,31(1):21.
ZHENG Yu-min,WANG Zi-zheng,WANG Feng,et al.Epidermal growth factor receptor targeted molecularly therapies of cancers[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(2):21.
[18]袁卫红,罗志航,彭荣宗,等.肺癌与表皮生长因子及其受体关系的研究[J].国际放射医学核医学杂志,2006,30(5):261.
YUAN Wei-hong,LUO Zhi-hang,PENG Rong-zong,et al.The study on the correlation between EGF, EGFR and lung carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):261.
[19]何蕊,朱高红.甲状腺髓样癌靶向治疗的研究进展[J].国际放射医学核医学杂志,2018,(2):154.[doi:10.3760/cma.j.issn.1673-4114.2018.02.010]
He Rui,Zhu Gaohong.Research status of medullary thyroid carcinoma targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(2):154.[doi:10.3760/cma.j.issn.1673-4114.2018.02.010]